https://www.selleckchem.com/pr....oducts/pemigatinib-i
We report the prevalence and change in severity of chronic kidney disease (CKD) in DISCOVER, a global, 3-year, prospective, observational study of patients with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy. CKD stages were defined according to estimated glomerular filtration rate (eGFR). Overall, 7843 patients from 35 countries had a baseline serum creatinine measurement. Of these (56.7% male; mean age 58.1 years; mean eGFR 87.5 mL/min/1.73 m2 ), baseline prevalence estimates for stage 0-1, 2, 3 a
Like
Comment
Share
